Conditions: Rosacea Erythema
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 64
Healthy volunteers: no

Brief summary:
This study will evaluate the safety and tolerability of AGN-199201 for the treatment of erythema associated with rosacea.

Detailed description:

Arms:
arm 1: AGN-199201 Formulation A applied to one side of the face and Formulation B applied to the other side of the face twice daily. arm 2: AGN-199201 Formulation B applied to one side of the face and Formulation C applied to the other side of the face twice daily. arm 3: AGN-199201 Formulation C applied to one side of the face and Formulation A applied to the other side of the face twice daily. arm 4: AGN-199201 Formulation A applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily. arm 5: AGN-199201 Formulation B applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily. arm 6: AGN-199201 Formulation C applied to one side of the face and AGN-199201 Vehicle applied to the other side of the face twice daily. arm 7: AGN-199201 Formulation A applied to both sides of the face twice daily. arm 8: AGN-199201 Formulation B applied to both sides of the face twice daily. arm 9: AGN-199201 Formulation C applied to both sides of the face twice daily. arm 10: AGN-199201 Vehicle (Placebo) applied to both sides of the face twice daily.

Interventions: intervention 1: AGN-199201 Formulation A intervention 2: AGN-199201 Formulation B intervention 3: AGN-199201 Formulation C intervention 4: AGN-199201 Vehicle
Intervention descriptions: intervention 1: AGN-199201 Formulation A applied to the face as per protocol twice daily. intervention 2: AGN-199201 Formulation B applied to the face as per protocol twice daily. intervention 3: AGN-199201 Formulation C applied to the face as per protocol twice daily. intervention 4: AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.

Protocol document: